RMTI up +13.08% percent right now. $RMTI High is a
Post# of 144506
Posted On: 11/09/2014 4:41:18 AM
RMTI up +13.08% percent right now. $RMTI High is at 11.75 and the Low 10.16 with current volume of 3,464,300.
Recent News posted below.
RMTI Rockwell Medical Technologies Recent Headline News
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Rockwell Medical, Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Fri Nov 07, 1:41PM CST
Levi & Korsinsky, LLP is investigating Rockwell Medical, Inc. (NasdaqGM:RMTI) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
RMTI: 10.55 (+1.22)
Rockwell Medical (RMTI) Stock Soars After FDA Panel Votes in Favor of Its Iron Replacement Therapy
at The Street - Fri Nov 07, 9:27AM CST
Shares of Rockwell Medical (RMTI) surged in morning trading Friday after an FDA panel voted to support its iron replacement therapy Triferic.
RMTI: 10.55 (+1.22)
Rockwell Dialysis Therapy Wins Panel Support But Final FDA Approval? Not So Fast.
at The Street - Fri Nov 07, 6:44AM CST
A deeply flawed FDA advisory panel voted to support Rockwell's iron replacement therapy for dialysis. FDA still must decide if the product is approvable.
RMTI: 10.55 (+1.22)
FDA Advisory Committee Recommends Rockwell Medical's Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
GlobeNewswire - Thu Nov 06, 5:23PM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food & Drug Administration (FDA) recommended that the Phase 3 Triferic efficacy and safety results support a positive benefit/risk to treat iron loss to maintain hemoglobin in patients with hemodialysis-dependent stage 5 chronic kidney disease (CKD). The ODAC voted in favor of Triferic by a vote of 8 to 3.
RMTI: 10.55 (+1.22)
Critical Alerts For Office Depot, Rockwell Medical, Estee Lauder, Discovery Communications and Keurig Green Mountain Released By InvestorsObserver
PR Newswire - Wed Nov 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ODP, RMTI, EL, DISCA and GMCR.
GMCR: 152.90 (-0.16), DISCA: 32.62 (-0.28), ODP: 6.50 (+0.13), RMTI: 10.55 (+1.22), EL: 72.58 (+0.75)
Rockwell Medical (RMTI) Worth Watching: Stock Surges 21.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:25AM CST
Rockwell Medical (RMTI) was a big mover last session, as the company saw its shares surge over 21% on the day.
ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), GWPH: 73.97 (-0.41), RMTI: 10.55 (+1.22)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HBNK: 19.91 (+0.15), ASMI: 41.20 (-0.20), VBFC: 18.65 (-1.32), RRGB: 68.26 (-0.01), SAPE: 24.67 (+0.03), ODP: 6.50 (+0.13), RMTI: 10.55 (+1.22), MTEX: 21.66 (-0.57), JAXB: 11.69 (+1.08), ALQA: 5.13 (+0.25)
FDA Review of Rockwell's Dialysis Therapy Raises Doubts About Need
at The Street - Tue Nov 04, 9:22AM CST
Briefing documents for Thursday's FDA advisory panel reviewing Rockwell Medical's RMTI Triferic iron replacement therapy were posted to the agency's web site this morning.
RMTI: 10.55 (+1.22)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 106.45 (-0.49), CLVS: 58.31 (-0.26), ARWR: 6.06 (-0.24), ACHN: 10.11 (-0.15), MRK: 59.34 (+0.08), RTRX: 10.38 (+0.29), RGLS: 22.08 (+2.42), EPZM: 23.75 (+0.19), AGIO: 72.06 (-11.03), RMTI: 10.55 (+1.22), ARNA: 4.26 (+0.01), KERX: 16.73 (-0.47)
Rockwell Medical Schedules Third Quarter 2014 Investor Conference Call
GlobeNewswire - Thu Oct 30, 3:50PM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss third quarter results on Monday, November 10, 2014 at 4:30pm Eastern Time.
RMTI: 10.55 (+1.22)
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta
at The Street - Fri Oct 24, 7:28AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 2.16 (-0.02), RNA: 12.14 (+0.08), SRPT: 16.12 (-0.14), RMTI: 10.55 (+1.22)
Rockwell Medical Announces FDA Advisory Committee Review of Triferic for the Treatment of Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
GlobeNewswire - Thu Oct 09, 6:30AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food & Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Triferic on November 6, 2014 in an afternoon session. Triferic is Rockwell's investigational drug for the treatment of iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic is under review by the Office of Hematology and Oncology Products (OHOP) Division of Hematology products. The proposed indication for Triferic is for the treatment of iron loss or iron deficiency to maintain hemoglobin in patients with hemodialysis dependent chronic kidney disease and to reduce the prescribed dose of erythropoiesis stimulating agents (ESAs) required to maintain desired hemoglobin levels. The FDA accepted the Triferic NDA for review on May 28, 2014. The PDUFA date for the FDA to complete its review of the Triferic NDA is January 24, 2015.
RMTI: 10.55 (+1.22)
Baxter International Up on Distribution Deal with Rockwell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 11:49AM CDT
Under the terms of the agreement, Baxter (BAX) can also expand the distribution agreement for two additional 5-year terms upon meeting certain sales milestones, coupled with a $7.5 million payment related to the first extension.
ICUI: 71.16 (-0.89), ZLTQ: 27.49 (-0.25), BAX: 70.61 (-0.99), RMTI: 10.55 (+1.22)
Rockwell Medical Receives $8 Million in Cash Via Exercise of Warrants
GlobeNewswire - Tue Oct 07, 6:30AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it received $8,003,578.05 in cash on 838,071 warrants exercised at $9.55 per warrant. The warrants had an expiration date of October 5, 2014.
RMTI: 10.55 (+1.22)
Critical Alerts For Rockwell Medical, Transocean, Dollar Tree, Globalstar and Sohu.com Released By InvestorsObserver
PR Newswire - Mon Oct 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for RMTI, RIG, DLTR, GSAT and SOHU.
DLTR: 61.56 (-0.55), RIG: 29.71 (-0.21), SOHU: 50.34 (+1.15), RMTI: 10.55 (+1.22), GSAT: 2.62 (+0.14)
Rockwell Medical (RMTI) Jumps: Stock Gains 15.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:25AM CDT
Rockwell Medical (RMTI) was a big mover last session, with shares rising nearly 16% on the day.
ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), EGRX: 12.48 (-0.17), RMTI: 10.55 (+1.22)
Baxter Gets Shot In The Arm From Rockwell Deal
at Investor's Business Daily - Fri Oct 03, 5:09PM CDT
Baxter International gapped up and bolted above its 200-day moving average Friday. The move came on news that Baxter International (BAX) subsidiary Baxter Healthcare would commercialize Rockwell Medical's (RMTI) hemodialysis-concentrate product line...
BAX: 70.61 (-0.99), RMTI: 10.55 (+1.22)
Nasdaq stocks posting largest volume increases
AP - Fri Oct 03, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LGCY: 21.26 (+0.15), QBAK: 1.16 (+0.02), LAKE: 13.29 (+0.42), RMTI: 10.55 (+1.22), PLMT: 15.87 (+0.37), SMPL: 16.72 (-0.03)
Recent News posted below.
RMTI Rockwell Medical Technologies Recent Headline News
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Rockwell Medical, Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Fri Nov 07, 1:41PM CST
Levi & Korsinsky, LLP is investigating Rockwell Medical, Inc. (NasdaqGM:RMTI) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
RMTI: 10.55 (+1.22)
Rockwell Medical (RMTI) Stock Soars After FDA Panel Votes in Favor of Its Iron Replacement Therapy
at The Street - Fri Nov 07, 9:27AM CST
Shares of Rockwell Medical (RMTI) surged in morning trading Friday after an FDA panel voted to support its iron replacement therapy Triferic.
RMTI: 10.55 (+1.22)
Rockwell Dialysis Therapy Wins Panel Support But Final FDA Approval? Not So Fast.
at The Street - Fri Nov 07, 6:44AM CST
A deeply flawed FDA advisory panel voted to support Rockwell's iron replacement therapy for dialysis. FDA still must decide if the product is approvable.
RMTI: 10.55 (+1.22)
FDA Advisory Committee Recommends Rockwell Medical's Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
GlobeNewswire - Thu Nov 06, 5:23PM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food & Drug Administration (FDA) recommended that the Phase 3 Triferic efficacy and safety results support a positive benefit/risk to treat iron loss to maintain hemoglobin in patients with hemodialysis-dependent stage 5 chronic kidney disease (CKD). The ODAC voted in favor of Triferic by a vote of 8 to 3.
RMTI: 10.55 (+1.22)
Critical Alerts For Office Depot, Rockwell Medical, Estee Lauder, Discovery Communications and Keurig Green Mountain Released By InvestorsObserver
PR Newswire - Wed Nov 05, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ODP, RMTI, EL, DISCA and GMCR.
GMCR: 152.90 (-0.16), DISCA: 32.62 (-0.28), ODP: 6.50 (+0.13), RMTI: 10.55 (+1.22), EL: 72.58 (+0.75)
Rockwell Medical (RMTI) Worth Watching: Stock Surges 21.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:25AM CST
Rockwell Medical (RMTI) was a big mover last session, as the company saw its shares surge over 21% on the day.
ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), GWPH: 73.97 (-0.41), RMTI: 10.55 (+1.22)
Nasdaq stocks posting largest percentage increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HBNK: 19.91 (+0.15), ASMI: 41.20 (-0.20), VBFC: 18.65 (-1.32), RRGB: 68.26 (-0.01), SAPE: 24.67 (+0.03), ODP: 6.50 (+0.13), RMTI: 10.55 (+1.22), MTEX: 21.66 (-0.57), JAXB: 11.69 (+1.08), ALQA: 5.13 (+0.25)
FDA Review of Rockwell's Dialysis Therapy Raises Doubts About Need
at The Street - Tue Nov 04, 9:22AM CST
Briefing documents for Thursday's FDA advisory panel reviewing Rockwell Medical's RMTI Triferic iron replacement therapy were posted to the agency's web site this morning.
RMTI: 10.55 (+1.22)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 106.45 (-0.49), CLVS: 58.31 (-0.26), ARWR: 6.06 (-0.24), ACHN: 10.11 (-0.15), MRK: 59.34 (+0.08), RTRX: 10.38 (+0.29), RGLS: 22.08 (+2.42), EPZM: 23.75 (+0.19), AGIO: 72.06 (-11.03), RMTI: 10.55 (+1.22), ARNA: 4.26 (+0.01), KERX: 16.73 (-0.47)
Rockwell Medical Schedules Third Quarter 2014 Investor Conference Call
GlobeNewswire - Thu Oct 30, 3:50PM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss third quarter results on Monday, November 10, 2014 at 4:30pm Eastern Time.
RMTI: 10.55 (+1.22)
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta
at The Street - Fri Oct 24, 7:28AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 2.16 (-0.02), RNA: 12.14 (+0.08), SRPT: 16.12 (-0.14), RMTI: 10.55 (+1.22)
Rockwell Medical Announces FDA Advisory Committee Review of Triferic for the Treatment of Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
GlobeNewswire - Thu Oct 09, 6:30AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food & Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Triferic on November 6, 2014 in an afternoon session. Triferic is Rockwell's investigational drug for the treatment of iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic is under review by the Office of Hematology and Oncology Products (OHOP) Division of Hematology products. The proposed indication for Triferic is for the treatment of iron loss or iron deficiency to maintain hemoglobin in patients with hemodialysis dependent chronic kidney disease and to reduce the prescribed dose of erythropoiesis stimulating agents (ESAs) required to maintain desired hemoglobin levels. The FDA accepted the Triferic NDA for review on May 28, 2014. The PDUFA date for the FDA to complete its review of the Triferic NDA is January 24, 2015.
RMTI: 10.55 (+1.22)
Baxter International Up on Distribution Deal with Rockwell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 11:49AM CDT
Under the terms of the agreement, Baxter (BAX) can also expand the distribution agreement for two additional 5-year terms upon meeting certain sales milestones, coupled with a $7.5 million payment related to the first extension.
ICUI: 71.16 (-0.89), ZLTQ: 27.49 (-0.25), BAX: 70.61 (-0.99), RMTI: 10.55 (+1.22)
Rockwell Medical Receives $8 Million in Cash Via Exercise of Warrants
GlobeNewswire - Tue Oct 07, 6:30AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it received $8,003,578.05 in cash on 838,071 warrants exercised at $9.55 per warrant. The warrants had an expiration date of October 5, 2014.
RMTI: 10.55 (+1.22)
Critical Alerts For Rockwell Medical, Transocean, Dollar Tree, Globalstar and Sohu.com Released By InvestorsObserver
PR Newswire - Mon Oct 06, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for RMTI, RIG, DLTR, GSAT and SOHU.
DLTR: 61.56 (-0.55), RIG: 29.71 (-0.21), SOHU: 50.34 (+1.15), RMTI: 10.55 (+1.22), GSAT: 2.62 (+0.14)
Rockwell Medical (RMTI) Jumps: Stock Gains 15.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:25AM CDT
Rockwell Medical (RMTI) was a big mover last session, with shares rising nearly 16% on the day.
ICUI: 71.16 (-0.89), ABAX: 51.63 (-2.21), EGRX: 12.48 (-0.17), RMTI: 10.55 (+1.22)
Baxter Gets Shot In The Arm From Rockwell Deal
at Investor's Business Daily - Fri Oct 03, 5:09PM CDT
Baxter International gapped up and bolted above its 200-day moving average Friday. The move came on news that Baxter International (BAX) subsidiary Baxter Healthcare would commercialize Rockwell Medical's (RMTI) hemodialysis-concentrate product line...
BAX: 70.61 (-0.99), RMTI: 10.55 (+1.22)
Nasdaq stocks posting largest volume increases
AP - Fri Oct 03, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LGCY: 21.26 (+0.15), QBAK: 1.16 (+0.02), LAKE: 13.29 (+0.42), RMTI: 10.55 (+1.22), PLMT: 15.87 (+0.37), SMPL: 16.72 (-0.03)
(0)
(0)Scroll down for more posts ▼